Journal of Rehabilitation Sciences & Research

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Evaluating the Predictive Power of Cognitive Assessment Tools for Cortical Hypometabolism in Alzheimer’s Disease

Document Type : Original Articles

Authors

1 Department of speech therapy, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Speech Therapy, School of Rehabilitation Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Speech therapy, Orthopedic & Rehabilitation Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

5 Department of Biostatistics, School of Medicine, Trauma Research Center, Shiraz University of Medical Science, Shiraz, Iran

6 Department of Psychology, Cognitive and Neuroscience research Center (CNRC), Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

7 The Northern California Institute for Research and Education.

10.30476/jrsr.2024.103367.1501

Abstract

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss and cognitive decline. One of the leading theories explaining AD pathology is the emergence of cortical hypometabolism. This study aimed to investigate the association between cortical hypometabolism and various cognitive assessment tools across the dementia spectrum.
Methods: This cross-sectional and longitudinal study utilized data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), including 1,048 participants: 291 cognitively normal (CN), 579 with mild cognitive impairment (MCI), and 178 with AD. Fluorodeoxyglucose positron emission tomography (FDG-PET) data (as an indicator of hypometabolism) and cognitive assessment scores—including the Alzheimer’s Disease Assessment Scale (ADAS11 and ADAS13 subtests), Montreal Cognitive Assessment (MoCA), Everyday Cognition Scale (ECog), and Mini-Mental State Exam (MMSE)—were analyzed. Statistical methods included ANOVA, multiple regression, and ROC/AUC analyses.
Results: Linear regression revealed that ADAS11, ADAS13, and MMSE significantly predicted PET scores in the MCI group (p=0.002, p=0.002, p=0.017, respectively), while MoCA predicted PET scores in the CN group (β=0.016, p=0.045). ROC analysis showed that ADAS13 had the greatest discriminative capacity (AUC=0.786), followed by ADAS11 (AUC=0.767). Over time, PET scores declined significantly across all groups, with the AD group showing the largest decline. At 24 months, PET scores in the CN and MCI groups were notably higher than those in the AD group (p<0.001).
Conclusion: ADAS11 and ADAS13 can effectively differentiate between normal and abnormal cortical hypometabolism. Among all cognitive measures, ADAS13 demonstrated the highest discriminative ability, making it a valuable tool for clinicians and researchers in the early detection and longitudinal monitoring of Alzheimer’s disease.

Highlights

Salime Jafari

Keywords

References
  1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American journal of public health. 1998;88(9):1337-42.
  2. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. Journal of Alzheimer's Disease. 2013;33(s1):S405-S16.
  3. Scheltens P, Blennow K, Breteler MM, De Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease. The Lancet. 2016;388(10043):505-17.
  4. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. Journal of Nuclear Medicine. 2006;47(11):1778-86.
  5. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Annals of the New York Academy of Sciences. 2008;1147(1):180-95.
  6. Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. Journal of neuroscience research. 2017;95(4):943-72.
  7. Landau S, Harvey D, Madison C, Reiman E, Foster N, Aisen P, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75(3):230-8.
  8. Verclytte S, Lopes R, Lenfant P, Rollin A, Semah F, Leclerc X, et al. Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG‐PET in early‐onset Alzheimer's disease. Journal of Neuroimaging. 2016;26(2):207-12.
  9. Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I, et al. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Molecular psychiatry. 2018;23(7):1666-73.
  10. Chételat G, Desgranges B, de la Sayette V, Viader F, Berkouk K, Landeau B, et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain. 2003;126(9):1955-67.
  11. Nishi H, Sawamoto N, Namiki C, Yoshida H, Thuy DHD, Ishizu K, et al. Correlation between cognitive deficits and glucose hypometabolism in mild cognitive impairment. Journal of Neuroimaging. 2010;20(1):29-36.
  12. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11 C] PIB,[18 F] FDDNP and [18 F] FDG PET. European journal of nuclear medicine and molecular imaging. 2012;39:990-1000.
  13. Edison P, Archer H, Hinz R, Hammers A, Pavese N, Tai Y, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C] PIB and [18F] FDG PET study. Neurology. 2007;68(7):501-8.
  14. Benvenutto A, Giusiano B, Koric L, Gueriot C, Didic M, Felician O, et al. Imaging biomarkers of neurodegeneration in Alzheimer’s disease: Distinct contributions of cortical MRI atrophy and FDG-PET hypometabolism. Journal of Alzheimer's Disease. 2018;65(4):1147-57.
  15. Mohs RC. The Alzheimer's disease assessment scale. International psychogeriatrics. 1996;8(2):195-203.
  16. Teng E, Chui H. The modified mini-mental state examination (3MS). Can J Psychiatry. 1987;41(2):114-21.
  17. Schöll M, Maass A. Does early cognitive decline require the presence of both tau and amyloid-β? Brain. 2020;143(1):10-3.
  18. Bellio M, Oxtoby NP, Walker Z, Henley S, Ribbens A, Blandford A, et al. Analyzing large Alzheimer's disease cognitive datasets: considerations and challenges. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12135.
  19. Athilingam P, Visovsky C, Elliott AF, Rogal PJ. Cognitive screening in persons with chronic diseases in primary care: Challenges and recommendations for practice. American Journal of Alzheimer's Disease & Other Dementias®. 2015;30(6):547-58.
  20. Ellingsen KM. Standardized assessment of cognitive development: Instruments and issues. Early childhood assessment in school and clinical child psychology. 2016:25-49.
  21. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's & Dementia. 2017;13(5):561-71.
  22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. The American journal of psychiatry. 1984;141(11):1356-64.
  23. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Disease & Associated Disorders. 1997;11:13-21.
  24. Folstein MF, Robins LN, Helzer JE. The mini-mental state examination. Archives of general psychiatry. 1983;40(7):812-.
  25. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22(4):531.
  26. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of aging. 2011;32(7):1207-18.
  27. Ou Y-N, Xu W, Li J-Q, Guo Y, Cui M, Chen K-L, et al. FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study. Alzheimer's research & therapy. 2019;11:1-11.
  28. Costa AS, Reich A, Fimm B, Ketteler ST, Schulz JB, Reetz K. Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early Alzheimer's disease. Dementia and geriatric cognitive disorders. 2014;37(1-2):95-103.
  29. Krishnan K, Rossetti H, Hynan LS, Carter K, Falkowski J, Lacritz L, et al. Changes in Montreal Cognitive Assessment scores over time. Assessment. 2017;24(6):772-7.
  30. Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal Cognitive Assessment Memory Index Score (MoCA‐MIS) as a Predictor of Conversion from Mild Cognitive Impairment to A lzheimer's Disease. Journal of the American Geriatrics Society. 2014;62(4):679-84.
  31. Hojjati SH, Babajani-Feremi A. Seeing beyond the symptoms: biomarkers and brain regions linked to cognitive decline in Alzheimer's disease. Front Aging Neurosci. 2024;16:1356656.
  32. Sabbagh MN, Boada M, Borson S, Chilukuri M, Dubois B, Ingram J, et al. Early detection of mild cognitive impairment (MCI) in primary care. The Journal of prevention of Alzheimer's disease. 2020;7:165-70.
  33. Lü W, Zhang M, Yu W, Kuang W, Chen L, Zhang W, et al. Differentiating Alzheimer's disease from mild cognitive impairment: a quick screening tool based on machine learning. BMJ Open. 2023;13(12):e073011.
  34. Zhou B, Nakatani E, Teramukai S, Nagai Y, Fukushima M, Initiative AsDN. Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. Journal of Alzheimer's Disease. 2012;30(2):367-75.
  35. Gorji HT, Khoei TT, Kaabouch N, editors. Biomarkers Selection Toward Early Detection of Alzheimer's Disease. 2020 IEEE International Conference on Electro Information Technology (EIT); 2020: IEEE.
  36. Aziz SAA, Saripan MI, Ibrahim N, Saad FFA, Suppiah S, Ismail SIF, et al., editors. Combining ADAS-Cog Assessment with Hypometabolic Region of 18F-FDG PET/CT Brain Imaging for Alzheimer's Disease Detection. 2020 IEEE-EMBS Conference on Biomedical Engineering and Sciences (IECBES); 2021: IEEE.
  37. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of neurology. 2012;72(4):578-86.
  38. Park KW, Ko JH, Choi N, Jo S, Park YJ, Lee E-J, et al. Cortical hypometabolism associated with cognitive impairment of multiple system atrophy. Parkinsonism & Related Disorders. 2020;81:151-6.
  39. Lerch O, Ferreira D, Stomrud E, van Westen D, Tideman P, Palmqvist S, et al. Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns. Alzheimers Res Ther. 2024;16(1):153.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Journal of Rehabilitation Sciences & Research
Volume 12, Issue 4
December 2025
Pages 132-142
Files
Share
How to cite
Statistics